Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)

Do you consider a stock's sales trends when comparing names? For ideas on how to start your own sales analysis, we ran a screen.

We began by screening the healthcare sector for stocks with high growth prospects, with 5-year projected EPS growth above 15%.

We then screened these names for those with strong trends in revenue compared to inventory over the last year. We screened for companies seeing faster growth in revenue than inventory over the last year. Since inventory represents the portion of goods not yet sold, faster growth in revenue than inventory is considered a good sign.

To screen for healthy liquidity, we also only focused on those companies with inventory declining as a percent of current assets.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for up to six of the stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.

We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.

Do you think these companies have strong sales trends? Use this list as a starting point for your own analysis.

List sorted by increase in revenue over the last year.

1. Anika Therapeutics Inc. (NASDAQ:ANIK): Develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Market cap at $193.19M, most recent closing price at $13.87. 5-year projected EPS growth at 30.00%. Revenue grew by 22.32% during the most recent quarter ($14.36M vs. $11.74M y/y). Inventory grew by 3.53% during the same time period ($9.08M vs. $8.77M y/y). Inventory, as a percentage of current assets, decreased from 15.94% to 14.2% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

2. Cyberonics Inc. (NASDAQ:CYBX): Engages in the design, development, manufacture, sale, and marketing of implantable medical devices that provide vagus nerve stimulation therapy for the treatment of refractory epilepsy and treatment-resistant depression. Market cap at $1.09B, most recent closing price at $39.84. 5-year projected EPS growth at 26.25%. Revenue grew by 15.85% during the most recent quarter ($54.54M vs. $47.08M y/y). Inventory grew by -11.32% during the same time period ($13.95M vs. $15.73M y/y). Inventory, as a percentage of current assets, decreased from 10.98% to 10.33% during the most recent quarter (comparing 13 weeks ending 2012-01-27 to 13 weeks ending 2011-01-28).

3. Abaxis Inc. (NASDAQ:ABAX): Develops, manufactures, markets, and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements in the medical and veterinarian markets. Market cap at $742.67M, most recent closing price at $34.47. 5-year projected EPS growth at 17.50%. Revenue grew by 13.8% during the most recent quarter ($42.72M vs. $37.54M y/y). Inventory grew by -1.06% during the same time period ($19.6M vs. $19.81M y/y). Inventory, as a percentage of current assets, decreased from 15.97% to 15.38% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

4. Nxstage Medical, Inc. (NASDAQ:NXTM): Engages in the development, manufacture, and marketing of products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures in the United States. Market cap at $844.54M, most recent closing price at $15.20. 5-year projected EPS growth at 20.00%. Revenue grew by 12.64% during the most recent quarter ($56.95M vs. $50.56M y/y). Inventory grew by -4.79% during the same time period ($34.95M vs. $36.71M y/y). Inventory, as a percentage of current assets, decreased from 23.87% to 22.25% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

5. Novo Nordisk A/S (NYSE:NVO): Engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. Market cap at $94.44B, most recent closing price at $142.16. 5-year projected EPS growth at 15.33%. Revenue grew by 12.38% during the most recent quarter ($18,120M vs. $16,124M y/y). Inventory grew by -2.64% during the same time period ($9,433M vs. $9,689M y/y). Inventory, as a percentage of current assets, decreased from 25.98% to 23.83% during the most recent quarter (comparing 3 months ending 2011-12-31 to 3 months ending 2010-12-31).

6. Volcano Corporation (NASDAQ:VOLC): Designs, develops, manufactures, and commercializes a suite of intravascular ultrasound and functional measurement products used in the diagnosis and treatment of vascular and structural heart disease. Market cap at $1.56B, most recent closing price at $29.14. 5-year projected EPS growth at 26.00%. Revenue grew by 11.56% during the most recent quarter ($90.36M vs. $81M y/y). Inventory grew by -10.49% during the same time period ($39.26M vs. $43.86M y/y). Inventory, as a percentage of current assets, decreased from 13.79% to 12.17% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

7. ResMed Inc. (NYSE:RMD): Engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Market cap at $4.86B, most recent closing price at $33.45. 5-year projected EPS growth at 17.40%. Revenue grew by 11.43% during the most recent quarter ($349.07M vs. $313.26M y/y). Inventory grew by -10.49% during the same time period ($183.49M vs. $205M y/y). Inventory, as a percentage of current assets, decreased from 17.05% to 13.84% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

8. Trinity Biotech plc (NASDAQ:TRIB): Develops, manufactures, distributes, and sells diagnostic test kits and instrumentation worldwide. Market cap at $251.17M, most recent closing price at $11.50. 5-year projected EPS growth at 16.00%. Revenue grew by 7.4% during the most recent quarter ($20.03M vs. $18.65M y/y). Inventory grew by 3.54% during the same time period ($19.3M vs. $18.64M y/y). Inventory, as a percentage of current assets, decreased from 18.16% to 17.43% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

9. Orthofix International N.V. (NASDAQ:OFIX): Designs, develops, manufactures, markets, and distributes medical equipment used principally by musculoskeletal medical specialists for orthopedic applications. Market cap at $733.47M, most recent closing price at $39.35. 5-year projected EPS growth at 17.33%. Revenue grew by 2.86% during the most recent quarter ($143.14M vs. $139.16M y/y). Inventory grew by -2.91% during the same time period ($90.94M vs. $93.67M y/y). Inventory, as a percentage of current assets, decreased from 28.19% to 21.93% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

*Accounting data sourced from Google Finance, all other data sourced from Finviz.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Source: 9 High-Growth Healthcare Stocks With Strong Inventory Trends